beeldscherm schreef op 21 februari 2018 09:52:
It believes BioCryst's lead product candidate, BCX7353, for the treatment of hereditary angioedema "has a present value of well over $1.5 billion, more than three times the current market capitalization of BCRX."
onder het mom van, you got et pumped up,pumped up...wat is Ruconest dan waard...